Product
PD-1/PD-L1 inhibitors and anti-angiogenic agents
1 clinical trial
1 indication
Indication
Hepatocellular CarcinomaClinical trial
A Retrospective Study Comparing Interventional Therapy (TACE/HAIC) Combined With PD-1/PD-L1 Inhibitors and Anti-angiogenic Agents Versus PD-1/PD-L1 Inhibitors and Anti-angiogenic Agents Alone in the First-line Treatment of Intermediate and Advanced Hepatocellular Carcinoma Beyond up to SevenStatus: Not yet recruiting, Estimated PCD: 2024-08-01